We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) , one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Additionally, the companies created a joint venture (“JV”), thereby combining their consumer divisions to form a larger consumer health care business.
Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on adding cancer drugs to boost its pharma pipeline.
Meanwhile, like many of its peers, Glaxo is facing challenges in the form of stiff competition, genericization, pricing pressure and slowing growth in emerging markets. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been mixed so far, with the company’s earnings beating expectations twice in the trailing four quarters while missed in the other two. Overall, the company has delivered an average positive surprise of 3.74%.
Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Glaxo reported core earnings of 79 cents per American depositary share in the first quarter of 2019, which beat our consensus estimate of 66 cents. The company’s focus on cost control initiative has boosted margins.
Revenues Beat: Revenues were up 5% year over year at constant exchange rate (“CER”) to $10.1 billion (£7.7 billion). Revenues beat the Zacks Consensus Estimate of $9.86 billion.
Key Stats: While sales in Consumer Healthcare and Pharmaceuticals were up 1% and 2%. respectively, the Vaccines segment increased 20% at CER. New respiratory product sales grew 25% at CER.
2019 Guidance: Glaxo maintained its previous guidance for 2019. EPS is expected to decline by 5-9% at CER in 2019 which includes impact of Advair generic, acquisition of TESARO, joint venture with Pfizer for Consumer Healthcare business ad divestment of certain nutrition brands.
Share Price Impact: Shares rose almost 0.3% in pre-market trading.
Check back later for our full write up on GSK earnings report later!
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1
GlaxoSmithKline plc (GSK - Free Report) , one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Additionally, the companies created a joint venture (“JV”), thereby combining their consumer divisions to form a larger consumer health care business.
Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on adding cancer drugs to boost its pharma pipeline.
Meanwhile, like many of its peers, Glaxo is facing challenges in the form of stiff competition, genericization, pricing pressure and slowing growth in emerging markets. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been mixed so far, with the company’s earnings beating expectations twice in the trailing four quarters while missed in the other two. Overall, the company has delivered an average positive surprise of 3.74%.
Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Glaxo reported core earnings of 79 cents per American depositary share in the first quarter of 2019, which beat our consensus estimate of 66 cents. The company’s focus on cost control initiative has boosted margins.
Revenues Beat: Revenues were up 5% year over year at constant exchange rate (“CER”) to $10.1 billion (£7.7 billion). Revenues beat the Zacks Consensus Estimate of $9.86 billion.
Key Stats: While sales in Consumer Healthcare and Pharmaceuticals were up 1% and 2%. respectively, the Vaccines segment increased 20% at CER. New respiratory product sales grew 25% at CER.
2019 Guidance: Glaxo maintained its previous guidance for 2019. EPS is expected to decline by 5-9% at CER in 2019 which includes impact of Advair generic, acquisition of TESARO, joint venture with Pfizer for Consumer Healthcare business ad divestment of certain nutrition brands.
Share Price Impact: Shares rose almost 0.3% in pre-market trading.
Check back later for our full write up on GSK earnings report later!
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>